Interaction between Omeprazole and Gliclazide in Relation to CYP2C19 Phenotype

Interaction between Omeprazole and Gliclazide in Relation to CYP2C19 Phenotype

The antidiabetic drug gliclazide is partly metabolized by CYP2C19, the main enzyme involved in omeprazole metabolism. The aim of the study was to explore the interaction between omeprazole and gliclazide in relation to CYP2C19 phenotype using physiologically based pharmacokinetic (PBPK) modeling app...

Full description

Bibliographic Details
Main Authors:	Tanja Dujic, Sandra Cvijic, Amar Elezovic, Tamer Bego, Selma Imamovic Kadric, Maja Malenica, Alisa Elezovic, Ewan R. Pearson, Aida Kulo
Format:	Article
Language:	English
Published:	MDPI AG 2021-05-01
Series:	Journal of Personalized Medicine
Subjects:	omeprazole gliclazide CYP2C19 physiologically based pharmacokinetic modeling drug–drug interaction drug–drug–gene interaction
Online Access:	https://www.mdpi.com/2075-4426/11/5/367

Similar Items

Safety analysis of co-administering tacrolimus and omeprazole in renal transplant recipients – A review
by: Miłosz Miedziaszczyk, et al.
Published: (2023-10-01)

Omeprazol y clopidogrel asociado a trombosis de stent
by: Ricardo Amador García Hernández, et al.

Cardiovascular Outcomes Associated With Clinical Use of Citalopram and Omeprazole: A Nationwide Population‐Based Cohort Study
by: Wen‐Tung Wu, et al.
Published: (2019-10-01)

Drug–drug interaction of microdose and regular-dose omeprazole with a CYP2C19 inhibitor and inducer
by: Park G, et al.
Published: (2017-03-01)

Identification of Prognostic Signature and Gliclazide as Candidate Drugs in Lung Adenocarcinoma
by: Yang Cheng, et al.
Published: (2021-06-01)

CYP2C19*2 Polymorphism Is Associated with Impaired Oral Clearance of Gliclazide in Healthy Chinese
by: Chow E, et al.
Published: (2020-01-01)

Relevancia clínica de la interacción clopidogrel y omeprazol: revisión sistemática Clinical relevance of clopidogrel and omeprazole interaction: systematic review
by: Héctor Holguín, et al.
Published: (2012-01-01)

Clopidogrel and proton pump inhibitor (PPI) interaction: separate intake and a non-omeprazole PPI the solution?
by: Kenngott S, et al.
Published: (2010-05-01)

How Does Glycation Affect Binding Parameters of the Albumin-Gliclazide System in the Presence of Drugs Commonly Used in Diabetes? In Vitro Spectroscopic Study
by: Katarzyna Wiglusz, et al.
Published: (2021-06-01)

Bioavailability and Antidiabetic Activity of Gliclazide-Loaded Cubosomal Nanoparticles
by: Mohamed Nasr, et al.
Published: (2021-08-01)

The impact of CYP2C19 genotype on phenoconversion by concomitant medication
by: Laura M. de Jong, et al.
Published: (2023-06-01)

The anti ulcer effect of omeprazole is modified by Nigella sativa (Black Cumin) in ethanol induced gastric ulceration in rabbits
by: Jawad Ahmed, et al.
Published: (2020-12-01)

Omeprazole-induced galactorrhea in kidney transplant patients—a case report
by: Choki Dorji, et al.
Published: (2022-03-01)

Analysis of CYP2C9*2, CYP2C19*2, and CYP2D6*4 polymorphisms in patients with type 2 diabetes mellitus
by: Sabina Semiz, et al.
Published: (2010-11-01)

Does celecoxib inhibit agomelatine metabolism via CYP2C9 or CYP1A2?
by: Yasar U
Published: (2018-07-01)

A Physiologically-Based Pharmacokinetic (PBPK) Model Network for the Prediction of CYP1A2 and CYP2C19 Drug–Drug–Gene Interactions with Fluvoxamine, Omeprazole, S-mephenytoin, Moclobemide, Tizanidine, Mexiletine, Ethinylestradiol, and Caffeine
by: Tobias Kanacher, et al.
Published: (2020-12-01)

Assessment of Substrate Status of Drugs Metabolized by Polymorphic Cytochrome P450 (CYP) 2 Enzymes: An Analysis of a Large-Scale Dataset
by: Jakob Sommer, et al.
Published: (2024-01-01)

Effects of astragaloside IV on the pharmacokinetics of omeprazole in rats
by: Wei Liu, et al.
Published: (2019-01-01)

Importance of Pharmacogenetics and Drug–Drug Interactions in a Kidney Transplanted Patient
by: Julia Concha, et al.
Published: (2023-07-01)

Assessing Drug Interaction and Pharmacokinetics of Loxoprofen in Mice Treated with CYP3A Modulators
by: Sanjita Paudel, et al.
Published: (2019-09-01)

Important application value of injectable hydrogels loaded with omeprazole Schiff base complex in the treatment of pancreatitis
by: Ma Jingrong, et al.
Published: (2023-11-01)

Antineoplastic effects of sodium dichloroacetate and omeprazole, alone or in combination, on canine oral mucosal melanoma cells
by: Gabriela F. Toledo, et al.
Published: (2023-07-01)

Influence of curcumin on the pharmacodynamics and pharmacokinetics of gliclazide in animal models
by: Vatsavai LK, et al.
Published: (2016-11-01)

Anemarsaponin BII inhibits the activity of CYP3A4, 2D6, and 2E1 with human liver microsomes
by: Mingwei Wang, et al.
Published: (2020-01-01)

Pharmaceutical intervention in the rational use of intravenous omeprazole
by: Eduardo Silva Araújo, et al.
Published: (2020-01-01)

Analysis of Combined Effect of CYP2C19 Genetic Polymorphism and Proton Pump Inhibitors Coadministration on Trough Concentration of Voriconazole
by: Mafuru M, et al.
Published: (2021-11-01)

Simultaneous determination of 9 CYP450 enzymes in human liver microsomes using LC-MS/MS
by: SHI Zhongbo, et al.
Published: (2021-02-01)

Pinelliae Rhizoma, a Toxic Chinese Herb, Can Significantly Inhibit CYP3A Activity in Rats
by: Jinjun Wu, et al.
Published: (2015-01-01)

CYP450s-Activity Relations of Celastrol to Interact with Triptolide Reveal the Reasons of Hepatotoxicity of <i>Tripterygium wilfordii</i>
by: Chunhuan Jin, et al.
Published: (2019-06-01)

Characteristics and substantiation of the use of pellets as a modern dosage form on the market of Ukraine
by: Anna Yerkhova, et al.
Published: (2021-12-01)

Hypoglycemia possibly caused by CYP2C9-mediated drug interaction in combination with bucolome: a case report
by: Hiroki Tateishi, et al.
Published: (2021-11-01)

Inhibitory mechanism of vortioxetine on CYP450 enzymes in human and rat liver microsomes
by: Yunyun Zhan, et al.
Published: (2023-09-01)

In vitro and In silico studies of interactions of cathinone with human recombinant cytochrome P450 CYP(1A2), CYP2A6, CYP2B6, CYP2C8, CYP2C19, CYP2E1, CYP2J2, and CYP3A5
by: Sharoen Yu Ming Lim, et al.
Published: (2022-01-01)

Effects of glycyrrhizin on the pharmacokinetics of paeoniflorin in rats and its potential mechanism
by: Hongjuan Sun, et al.
Published: (2019-01-01)

Omeprazole Treatment Failure in Gastroesophageal Reflux Disease and Genetic Variation at the CYP2C Locus
by: Ping Siu Kee, et al.
Published: (2022-05-01)

Venetoclax (ABT-199) Might Act as a Perpetrator in Pharmacokinetic Drug–Drug Interactions
by: Johanna Weiss, et al.
Published: (2016-02-01)

Prevalence and Accuracy of Information on CYP2D6, CYP2C19, and CYP2C9 Related Substrate and Inhibitor Co-Prescriptions in the General Population: A Cross‐Sectional Descriptive Study as Part of the PharmLines Initiative
by: Muh. Akbar Bahar, et al.
Published: (2020-05-01)

Insights into CYP2B6-mediated drug–drug interactions
by: William D. Hedrich, et al.
Published: (2016-09-01)

In Vitro Assessment of CYP-Mediated Drug Interactions for Kinsenoside, an Antihyperlipidemic Candidate
by: Shaheed Ur Rehman, et al.
Published: (2016-06-01)

CYP3A5 Genotype-Dependent Drug-Drug Interaction Between Tacrolimus and Nifedipine in Chinese Renal Transplant Patients
by: Yilei Yang, et al.
Published: (2021-07-01)